v3.25.4
Notes to the consolidated statements of income - Other operating income and expense (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Other operating income and expense      
Foreign exchange gains € 359,962 € 352,041 € 280,323
Gains on right-of-use assets, from the sale of fixed assets, clinics and investments 9,136 29,579 33,921
Revaluation of certain investments 7,254 51,572 14,671
Income from strategic transactions and programs 17,795 116,607 60,843
Income attributable to consent agreement on foregone profits from sale of certain pharmaceuticals to non-associated companies 43,050 71,994 46,919
Other 90,902 138,325 78,570
Other operating income 528,099 760,118 515,247
Foreign exchange losses 403,756 375,098 315,821
Losses on right-of-use assets, from the sale of fixed assets, clinics and investments 8,143 14,923 29,082
Revaluation of certain investments 84,292 7,544  
Expenses from strategic transactions and programs 122,162 434,088 320,765
Other 102,304 101,285 98,625
Other operating expense 720,657 932,938 764,293
Income from revaluation of assets held for sale   14,896  
Gains from divestitures   89,248  
Reclassification adjustments of foreign currency translation amounts previously classified within other comprehensive income, included in expenses from strategic transactions and programs (61,520) (115,570) (17,125)
Legacy Portfolio Optimization      
Other operating income and expense      
Reclassification adjustments of foreign currency translation amounts previously classified within other comprehensive income, included in expenses from strategic transactions and programs € (60,415) € (120,885) € (19,422)